EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Robust Immunohistochemistry‐Based Classification for BRAF V600E ‐Mutant Colorectal Cancer With Clinical Implications

Chao Liu iD, Yuli Ruan, Tong Wu, Xindi Luan, Yue Ma, Hong Wang, Tianjiao Dang, Yiwen Ou, Bojun Wang, Chunhui Zhang, Hongxue Meng, Yanqiao Zhang iD

Cancer Science · 2026

DOI: 10.1111/cas.70231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Chao Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, the Key Project of Research and Development Plan in Heilongjiang Province, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF V600E‐mutant colorectal cancer (CRC) represents a distinct molecular subtype with considerable heterogeneity in tumor biology and therapeutic response. Although gene expression‐based classifications (BM1/BM2 subtypes) provide valuable insights into underlying molecular and immune features, their clinical application is limited by the need for high‐throughput sequencing. This study aims to establish an immunohistochemistry (IHC)‐based classification system to enable practical subtype stratification and aid prognostic and therapeutic evaluation. Using two independent cohorts (public dataset, n = 218; institutional cohort, n = 122), we performed differential expression analysis, machine learning modeling, and clinical feasibility evaluation. Fourteen candidate markers were identified, and a decision tree algorithm selected CD8 and ARHGEF17 as optimal classifiers. Based on these markers, two IHC‐based subtypes were established: iBM1 (CD8 + /ARHGEF17 − ) and iBM2 (CD8 − with any ARHGEF17 expression or CD8 + /ARHGEF17 + ). The IHC‐based subtypes showed concordance with transcriptomic BM subtypes (training: 82.69%, κ = 0.55; validation: 72.22%, κ = 0.44; prospective: 83.33%, κ = 0.57). Transcriptomic profiling revealed enrichment of immune activation and epithelial–mesenchymal transition in iBM1, and cell cycle‐related pathways in iBM2. In clinical validation, iBM1 was associated with poorer survival but greater sensitivity to immune checkpoint inhibitors. This IHC‐based classification provides a practical and accessible approach for BM subtype stratification, reflecting underlying molecular and immune characteristics, and may support prognostic assessment and therapeutic decision‐making in BRAF V600E‐mutant CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafColorectal NeoplasmsImmunohistochemistryBiomarkers, TumorHumansFemaleMutationMalePrognosisMiddle AgedAgedGene Expression ProfilingMachine LearningTranscriptome

Stichwörter der Autor:innen

BM subtypesBRAF V600E‐mutant colorectal cancerICIs therapyimmunohistochemistryprognostic

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin Medical University Cancer Hospital, Harbin, China.
  • Key Laboratory of Tumor Immunology in Heilongjiang, Harbin Medical University Cancer Hospital, Harbin, China.
  • Key Laboratory of Preservation of Human Genetic Resources and Disease Control, Harbin Medical University, Harbin, China.
  • Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.

ORCID-Profile: Chao Liu, Yanqiao Zhang

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • the Key Project of Research and Development Plan in Heilongjiang Province
  • the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Liu, C., Ruan, Y., Wu, T., Luan, X., Ma, Y., Wang, H., Dang, T., Ou, Y., Wang, B., Zhang, C., Meng, H., & Zhang, Y. (2026). A Robust Immunohistochemistry‐Based Classification for BRAF V600E ‐Mutant Colorectal Cancer With Clinical Implications. Cancer Science. https://doi.org/10.1111/cas.70231

Vancouver

Liu C, Ruan Y, Wu T, Luan X, Ma Y, Wang H, et al. A Robust Immunohistochemistry‐Based Classification for BRAF V600E ‐Mutant Colorectal Cancer With Clinical Implications. Cancer Science. 2026. doi:10.1111/cas.70231

BibTeX
@article{Liu2026,
  author = {Liu, Chao and Ruan, Yuli and Wu, Tong and Luan, Xindi and Ma, Yue and Wang, Hong and Dang, Tianjiao and Ou, Yiwen and Wang, Bojun and Zhang, Chunhui and Meng, Hongxue and Zhang, Yanqiao},
  title = {A Robust Immunohistochemistry‐Based Classification for BRAF V600E ‐Mutant Colorectal Cancer With Clinical Implications},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70231}
}
Kostenlos starten →